Baricitinib

More trials are needed to fully elucidate the cardiovascular, infection and malignancy risks linked to Janus kinase inhibitors in rheumatoid arthritis, said a presenter at the 2022 Association of Women in Rheumatology annual conference.

A 4 mg dose of baricitinib plus topical corticosteroids was associated with significant improvement over placebo in a phase 3 study of patients with moderate to severe atopic dermatitis, according to a study.

By most metrics, modern rheumatology drugs are safer and more effective than those used in previous eras.

The FDA has approved Olumiant, the first systemic medication for the treatment of alopecia areata, according to a press release.

The FDA has approved a new indication for Olumiant as a treatment for adults hospitalized with COVID-19 who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data.

A 4 mg dose of baricitinib was associated with significant improvement compared with placebo in alopecia areata disease severity, according to a study.

Baricitinib reduces structural joint damage progression in rheumatoid arthritis even among patients with who continue to exhibit moderate or high disease activity, according to data published in Annals of the Rheumatic Diseases.

Treatment with baricitinib reduced mortality in critically ill patients with COVID-19 receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, researchers reported in The Lancet Respiratory Medicine.

The WHO has issued a “strong recommendation” for baricitinib, in combination with corticosteroids, in the treatment of patients with severe or critical COVID-19.